ArticleFrontiers in oncology2026
Prognostic and biological significance of MRPL13 in multiple myeloma: evidence from multi-cohort, single-cell analyses.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a clonal plasma cell malignancy with high heterogeneity and poor prognosis. Mitochondrial ribosomal protein L13 (MRPL13) has been linked to tumor progression, but its role in MM remains unclear. Methods: We analyzed seven datasets comprising 3,117 patient samples from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study (referred to as the TCGA_MMRF cohort) and the Gene Expression Omnibus (GEO) database to evaluate the association between MRPL13 expression and overall survival (OS). Event-free survival (EFS) analysis was performed in the GSE24080 cohort, and progression-free survival (PFS) analysis was conducted in the GSE136337 cohort. We further analyzed single-cell transcriptomic profiles of 74,986 cells from 24 MM patients to delineate the expression landscape of MRPL13 across distinct cellular populations and functional subclusters and to assess its relationship with the immune microenvironment. We performed functional assays involving siRNA-mediated MRPL13 silencing to investigate its effects on MM cell proliferation and cell-cycle progression Results: High MRPL13 expression was associated with adverse clinical features and poor survival and was identified as a potential independent prognostic factor. Single-cell analysis revealed enrichment in metabolically active malignant plasma cells and an immunosuppressive microenvironment. Silencing MRPL13 inhibited proliferation and induced G0/G1 arrest. Conclusion: MRPL13 predicts poor prognosis and promotes MM progression through metabolic and immune regulation, supporting its potential as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.